Table 2.
Treatment | Short-term treatment |
Continuous treatment |
||||
---|---|---|---|---|---|---|
Treatment time (h) | 4 |
4 |
24 |
|||
Metabolic activation | -S9 |
+S9 |
-S9 |
|||
Concentration of test article (μg/mL) | RPD (%) | Cells with micronucleus (%) | RPD (%) | Cells with micronucleus (%) | RPD (%) | Cells with micronucleus (%) |
Negative controla | 100 | 0.6 | 100 | 0.7 | 100 | 0.6 |
62.5 | NE | 89 | NO | NE | ||
125 | NE | 84 | NO | NE | ||
250 | 86 | NO | 72 | 0.9 | 99 | 0.6 |
500 | 77 | NO | 68 | 0.9 | 102 | 0.6 |
750 | 81 | 0.7 | 41 | 0.8 | NE | |
1000 | 59 | 0.7 | 38 | NO | 100 | 0.6 |
1250 | 44 | 0.9 | NE | NE | ||
1500 | −13 | NO | NE | NE | ||
2000 | NE | NE | 103 | 0.7 | ||
Positive control b, c | NE | 49 | 1.9* | 68 | 4.0* |
Significantly different from the negative control by Fisher’s exact test: * p < 0.05.
RPD, Relative population doubling; NE, Not examined; NO, Not observed.
Water for injection.
Cyclophosphamide (1.5 μg/mL) in Short-term treatment with S9 mix.
Colchicine (0.006 μg/mL) in Continuous treatment.